CADTH recently released their annual business plan for 2020-2021. In this, the last year of their three-year strategic plan, CADTH aims to deliver on a number of priority initiatives, several of which may have implications for industry, as described below. 1) Operationalize the Life Cycle Approach to Health Technology Assessment (HTA) Under this priority initiative, CADTH signals their continued commitment to the life cycle approach to HTA via: enhancement … Read More →
HTA
CADTH released its Pharmaceutical Reviews Update — Issue 15 on April 29, 2020. Please find below MORSE Consulting’s summary of this update. Topic MORSE Note 1. COVID-19 Update CADTH will continue to deliver on core activities, including the completion of ongoing drug reviews and initiation of new reviews in accordance with target timelines, and progress reports will continue to be posted on the CADTH website. Pre-submission and expert committee meetings … Read More →
Toronto, April 27, 2020 – MORSE Consulting is pleased to release our April 2020 Update to the Canadian Reimbursement Trends and Timelines report – a comprehensive, credible and relevant source of market access intelligence. This 50+ PowerPoint report is aimed at assisting market access professionals plan for future launches and also serves as a valuable education tool for both internal and external stakeholders. What’s New in the April 2020 Update? … Read More →
Toronto, February 18, 2020 – MORSE Consulting is pleased to expand and strengthen our service offering with the addition of Anita Carrie and Roy Cairns. Affordability of effective and innovative medications within the current Canadian public funding model is becoming very challenging for the healthcare system. Increasing budgetary constraints coupled with complex treatments requiring consideration of different sources and levels of evidence are an issue for all stakeholders. To help … Read More →
Summary of CADTH Drug Portfolio Information Session Date: Monday, November 25, 2019 Time: 1:30 pm to 4:00 pm On November 25, 2019, CADTH hosted two information sessions in Toronto, Ontario for their Medical Device and Drug Portfolios. These annual sessions are an opportunity for stakeholders to get the latest information about priority initiatives and process changes. The summary below is separated into the following sections: Welcome and Strategic Overview … Read More →
Development of a framework for the generation and use of Real-World Evidence for cancer drug funding. The CanREValue Collaboration hosted a webinar on November 6, 2019 to introduce their preliminary framework and to outline the Stakeholder Feedback process. The slide deck that was presented, along with a recording can be accessed from the CanREValue website. The purpose of the CanReValue Collaboration is to develop a framework for Canadian provinces … Read More →
Toronto, September 18, 2019 – MORSE Consulting is pleased to launch the Canadian Reimbursement Trends and Timelines report – a  comprehensive, credible and relevant source of market access intelligence. The market access pathway in Canada is going through an unprecedented level of change and uncertainty. This 58-page PowerPoint report is aimed at not only helping market access professionals plan for future launches but can be a valuable education tool for … Read More →
Introduction MORSE Consulting is pleased to contribute its pCPA/public payer expertise with leading pricing and reimbursement experts and provide our respective views on how the new PMPRB regulations may impact the Canadian environment. These experts include: PMPRB: Joan McCormick, Principal Consultant – IQVIA HTA/Health Economics (HE): Sumeet Singh & Heather Cameron – Cornerstone Research Group Inc. Private Payers: Suzanne Lepage, Suzanne Lepage Consulting The purpose of this summary is two-fold: … Read More →
MORSE Consulting summary of CADTH update. On July 31, 2019 CADTH released its Pharmaceutical Reviews Update – Issue 9 and MORSE Consulting has prepared a brief summary of the important developments from this CADTH update. Consultations (Feedback to be provided by September 13, 2019) CADTH is inviting stakeholder comments and feedback on three proposals for the Pharmaceutical Review Programs. 1) Enhance the Transparency of CADTH’s Review Reports and Recommendations … Read More →
MORSE Consulting is pleased to release a new report entitled Spotlight on the Atlantic Provinces: pCPA Letter of Intent Conversion and Time-to-Listing Analysis. While the majority of Canadians have some form of prescription medication coverage, the speed and extent to which individual patients gain access to new therapies, can vary significantly. As new drugs (and expanded indications for existing drugs) are approved by Health Canada and become available for use … Read More →
Summary of Expensive Drugs for Rare Diseases (EDRD) Working Group Webinar Signals Decoded: Stakeholder consultation is underway on a supplemental process for complex/specialized drugs that builds upon the existing national HTA and reimbursement process to make responsive funding decisions with a focus on non-oncology therapies. The supplemental process is a significant development in EDRD policy and it looks to streamline the evaluation and reimbursement process of eligible drugs … Read More →
Panel 5: Patient Support Programs Panel Description: This session will help participants develop a better understanding of why PSPs are well-suited to support the development of outcomes-based agreements. It will suggest effective ways that PSPs can be developed to support data collection for HTA. Finally, current pCPA perspectives on PSPs and the opportunity for data collection within programs will be explored by this panel. Moderator: Allison Wills Panellists: Sang … Read More →
HTA Panel – CAHR Market Access 201: Flying Blind – Navigating Patient Access through Uncertainty
Panel 3: Health Technology Assessment Panel Description: Canada’s centralized HTA agency, CADTH, has recently released a new 3-year strategic plan that marks a shift from its previous vision. Noteworthy is the focus of recommendations on alignment of drug assessment with the priorities of the participating plans over all phases of the technology life cycle. Join us to hear CADTH describe their new strategic plan, how their mandate has evolved, … Read More →
On September 13th, 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) issued details on a new CADTH and Institut national d’excellence en santé et en services sociaux (INESSS) pilot project to jointly engage with clinical specialists. According to CADTH’s communication, the objectives of the pilot project are to: Strengthen the current pharmaceutical review processes used by CADTH and INESSS with respect to engagement with Canadian clinical specialists. … Read More →
A Comparison of Proposed INESSS and Current CADTH Evaluation Fees On February 21, 2018, the Quebec government released draft regulations (Gazette Officielle du Québec) that outline fees payable to Institut national d’excellence en santé et en services sociaux (INESSS) for the scientific evaluation of a drug or stable blood product. The fees are expected to vary based on the type of dossier submitted for scientific review with INESSS determining … Read More →
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2020 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
HTA - Info and details on - MORSE Consulting Inc.
